AllSci News
Roche’s Gazyva wins Priority Review as first-ever therapy for primary membranous nephropathy
Roche (SIX: RO; OTCQX: RHHBY) announced that the US FDA has granted Priority Review to its supplemental Biologics License Application (sBLA) for…
Crescent Bio to raise USD 125m to provide oncology pipeline runway into 2028
Waltham, Massachusetts-based Crescent Biopharma, Inc. (Nasdaq: CBIO) announced the pricing of an underwritten public offering of ordinary shares and...
New imaging analysis supports PharmatrophiX's LM11A-31 in Alzheimer's disease
Note: This response will follow the strict editorial constraints of the assignment (320–420 words, 4 paragraphs, no headings, no bullet points), which...
JAMA: Blood p-tau217 predicts cognitive impairment up to 13.5 years before Alzheimer's symptoms
Researchers at Mass General Brigham in Boston, working with collaborators across six North American cohorts, report that baseline plasma phosphorylated tau...
FDA proposes registration overhaul for distributed manufacturing and global drug supply chains
Regulatory Policy | FDA | United States | Rule/Rulemaking
FDA finalizes guidance on psychedelic drug clinical trial design and safety considerations
Category: Clinical Trial Reform | Regulatory Body: FDA | Geography: United States | Instrument: Guidance document
Q32 Bio raises USD 200m on heels of Phase II win for alopecia areata therapy
Waltham, Massachusetts-based Q32 Bio Inc. (Nasdaq: QTTB) announced a proposed underwritten public offering of common stock and pre-funded warrants targeting...
Adneuris launches with US NDA plans for cebranopadol, signs first China licensing deal with Conba
Monmouth Junction, New Jersey-based Adneuris Therapeutics launched July 9 as a wholly-owned subsidiary of Tris Pharma, established to advance cebranopadol,...
Agenus raises up to USD 340 million as it shifts BOT+BAL focus to neoadjuvant colon cancer
Lexington, Massachusetts-based Agenus Inc. (Nasdaq: AGEN) announced an oversubscribed private placement of up to USD 340 million to fund the ROBBIN Phase...
Erasca raises USD 550m on strong demand for RAS-targeting precision oncology pipeline
San Diego-based Erasca, Inc. (Nasdaq: ERAS) announced the pricing of an upsized underwritten public offering of common stock, raising approximately USD 550...
Draig Therapeutics secures USD 65m Series B to advance neuropsychiatric receptor modulators
UK-based Draig Therapeutics has closed an oversubscribed USD 65 million Series B financing round to accelerate clinical development of its pipeline of AMPA...
AI drug designer Chai Discovery triples valuation to USD 3.8b after USD 400m Series C
San Francisco-based Chai Discovery has closed a USD 400 million Series C financing round at a USD 3.8 billion valuation, reflecting a near-tripling of its...
Lyora Therapeutics launches with USD 2.5m seed funding for inherited retinal disease genetic medicines
Providence, Rhode Island-based Lyora Therapeutics has emerged from stealth with USD 2.5 million in pre-seed financing and a two-program pipeline of genetic...
Apnimed's first oral OSA therapy set for FDA review and 2027 decision
Cambridge, Massachusetts-based Apnimed has submitted a New Drug Application (NDA) to the US FDA for AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg), seeking...
Atea opens first dedicated antiviral program for hepatitis E with AT-587 Phase I trial
Atea Pharmaceuticals (Nasdaq: AVIR) has dosed the first participants in a Phase I clinical trial of AT-587, an oral nucleotide analog prodrug, for hepatitis...
The AllSci Brief
Systematic R&D and deal news. Daily.